Evotec SE ( EVO ) NASDAQ Global Select

Cena: 3.64 ( 2.82% )

Aktualizacja 08-22 21:57
NASDAQ Global Select
Branża: Drug Manufacturers - Specialty & Generic

Notowania:

Opis firmy:

Evotec SE działa jako partner odkrywania i rozwoju leków w branży farmaceutycznej i biotechnologicznej na całym świecie. Firma opracowuje produkty farmaceutyczne w różnych obszarach terapeutycznych, takich jak cukrzyca i powikłania cukrzycy, zwłóknienie, choroby zakaźne, choroby OUN, onkologia, ból i stan zapalny, immunologia, choroby rzadkie, choroby oddechowe i zdrowie kobiet. Ma umowy o współpracy z Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/s; Galapagos; Pfizer Inc.; Conba Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang Jingxin Pharmaceutical Co., Ltd; Kazia Therapeutics; Biologics Apeiron; i Takeda Pharmaceuticals. Firma była wcześniej znana jako Evotec AG i zmieniła nazwę na Evotec SE w kwietniu 2019 r. Evotec SE został zarejestrowany w 1993 roku i ma siedzibę w Hamburgu w Niemczech.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 5 007
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 94.8103
Ilość akcji: Brak danych
Debiut giełdowy: 2004-02-05
WWW: https://www.evotec.com
CEO: Dr. Christian Wojczewski
Adres: Essener Bogen 7
Siedziba: 22419 Hamburg
ISIN: US30050E1055
Wskaźniki finansowe
Kapitalizacja (USD) 1 292 575 113
Aktywa: 1 990 809 000
Cena: 3.64
Wskaźnik Altman Z-Score: 0.8
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -7.1
Ilość akcji w obrocie: 95%
Średni wolumen: 101 304
Ilość akcji 355 103 053
Wskaźniki finansowe
Przychody TTM 777 052 000
Zobowiązania: 1 022 340 000
Przedział 52 tyg.: 2.84 - 5.64
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.5
P/E branży: 22.5
Beta: 0.984
Raport okresowy: 2025-11-05
WWW: https://www.evotec.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Laetitia Rouxel Chief Financial Officer & Member of Management Board 967 430 1975
Dr. Craig Johnstone Ph.D. Chief Operating Officer & Member of Management Board 773 944 1970
Dr. Cord Dohrmann Ph.D. Chief Scientific Officer & Member of Management Board 632 634 1964
Dr. Matthias Evers Ph.D. Chief Business Officer & Member of Management Board 141 310 1973
Dr. Christian Dargel EVice President Global Head of Legal & Compliance 0 1971
Dr. Christian Wojczewski Chief Executive Officer 0 1972
Mr. Volker Braun Executive Vice President and Head of Global Investor Relations & ESG 0 0
Gabriele Hansen Senior Vice President & Head of Global Corporate Communications & Marketing 0 0
Ms. Anja Bosler Principal Accounting Officer and Senior Vice President of Group Accounting 0 0
Ms. Aurelie Dalbiez Chief People Officer & Member of Management Board 0 1977
Lista ETF z ekspozycją na akcje Evotec SE
Symbol ETF Ilość akcji Wartość
EFA 11 464 271 45 627 797
IWDG.L 8 496 865 25 595 805
IWLE.DE 7 351 517 25 595 805
EUNL.DE 6 431 107 22 391 210
SWDA.L 6 431 107 19 372 953
IWDA.AS 6 431 107 22 391 210
IWDD.AS 6 431 107 25 595 805
SWDA.MI 6 431 107 22 391 210
IWDA.L 6 431 107 25 595 805
IQLT 6 340 517 25 235 256
EFG 4 597 735 18 298 986
EUNK.DE 4 081 424 14 210 309
SMEA.L 4 080 653 12 292 486
IMEA.SW 4 080 572 13 197 825
ESGD 4 041 149 16 083 773
QDVX.DE 3 463 794 12 059 904
EQDS.L 3 463 139 10 432 299
IEUC.SW 3 414 189 11 042 535
IQQY.DE 3 171 589 11 042 535
IMEU.AS 3 171 589 11 042 535
IMEU.L 3 170 990 9 552 234
ISEU.L 3 170 734 12 619 519
IDEV 2 983 726 11 875 228
EXIE.DE 2 514 333 8 754 164
EXSA.DE 2 514 333 8 754 164
EXV9.DE 2 037 351 7 093 454
EWD 1 781 304 7 089 588
IEUR 1 696 873 6 753 552
IWFQ.L 1 598 032 4 813 884
IWQU.L 1 598 032 6 360 169
IS3Q.DE 1 598 032 5 563 876
SLMC.DE 1 584 788 5 517 761
SLMD.DE 1 584 788 5 517 761
SAEU.L 1 584 488 4 773 084
SDUE.L 1 584 488 4 773 084
ESIC.DE 1 467 607 5 109 773
ESIC.L 1 467 330 4 420 158
IBB 1 347 884 5 364 579
EXSD.DE 1 135 664 3 954 044
IEFA 975 511 88 238 688
EMID.L 902 321 3 141 615
EUMD.L 902 321 3 141 615
ACWI 850 357 3 384 419
IEV 793 539 3 158 285
ACWX 750 880 2 988 503
OMXS.L 714 713 2 152 987
OM3X.DE 714 488 27 809 433
WQDA.AS 628 177 2 500 143
WQDS.L 628 177 1 892 308
QDVW.DE 628 177 2 187 125
WQDV.L 628 177 2 500 143
EDM6.DE 552 228 1 922 695
EMNU.DE 552 228 1 922 695
EEUD.L 552 124 1 663 208
IQQU.DE 540 076 1 880 383
IEUX.L 539 974 1 626 606
IDWR.L 403 883 1 607 454
IWRD.L 403 883 1 216 650
IQQW.DE 403 883 1 406 201
IWRD.AS 403 883 1 406 201
CEMQ.DE 402 075 1 399 906
IEQD.L 402 075 1 399 906
IEFQ.L 401 999 1 210 975
VIGI 333 822 26 513 163
VGK 332 121 26 378 065
URTH 300 475 1 195 889
VEU 294 017 23 351 729
SDWD.L 287 907 1 145 868
SAWD.L 287 907 1 145 868
SNAW.DE 287 907 1 002 406
S6DW.DE 287 907 1 002 406
PLAY.AS 280 248 1 115 385
EMND.DE 254 816 887 194
EEWG.L 254 816 767 603
EDMW.DE 254 816 887 194
EEWD.L 254 816 1 014 168
EGMW.L 254 816 767 603
IBCH.DE 252 646 879 639
IWDE.L 252 646 879 639
RXI 176 726 703 368
IS3T.DE 128 681 448 028
IWSZ.L 128 681 512 149
IWFS.L 128 681 387 635
CRBN 119 158 474 249
WCDS.AS 111 204 442 590
36BB.DE 111 204 387 178
VYMI 108 087 8 584 600
IWDC.SW 88 849 287 363
IGRO 74 038 6 697 019
EUXS.L 72 998 219 898
XEF.TO 68 117 8 509 259
VWRP.L 67 001 4 004 108
VWRL.AS 67 001 4 627 136
VWRL.L 67 001 4 004 108
VWCE.DE 67 001 4 627 136
VWRA.L 67 001 5 283 928
VWRD.L 67 001 5 283 928
VGWL.DE 67 001 4 627 136
VEUR.AS 65 551 4 403 949
VWCG.L 65 551 5 027 769
VWCG.DE 65 551 4 403 949
VGEU.DE 65 551 4 403 949
VEUR.L 65 551 3 810 033
VEUD.L 65 551 5 027 769
VEUA.L 65 551 3 810 033
DBEF 61 775 5 553 830
VERX.DE 60 199 4 044 383
VERX.L 60 199 3 498 957
VERE.DE 60 199 4 044 383
VERG.L 60 199 3 498 957
VERE.L 60 199 4 617 270
VERX.AS 60 199 4 044 383
IWQE.MI 52 590 183 104
IQDF 45 870 4 100 185
CEMT.DE 41 640 144 978
IEFS.L 41 632 125 411
VHYA.L 30 302 2 389 719
VHYD.L 30 302 2 389 719
VGWD.DE 30 302 2 092 677
VHYG.L 30 302 1 810 905
VGWE.DE 30 302 2 092 677
VHYL.AS 30 302 2 092 677
VHYL.L 30 302 1 810 905
VIU.TO 27 251 2 932 456
FENI 24 741 2 252 481
IGWD.L 24 107 72 618
PABD 21 273 84 664
LCTD 20 613 82 041
EUPB.AS 18 512 64 452
EPAD.AS 18 512 64 452
VGVE.DE 16 296 1 125 413
VHVG.L 16 296 973 880
VDEV.L 16 296 1 285 158
VHVE.L 16 296 1 285 158
VEVE.L 16 296 973 880
VGVF.DE 16 296 1 125 413
TOK 11 500 45 769
XFH.TO 9 713 1 213 314
IEU.AX 9 075 1 270 429
XIN.TO 8 188 1 022 840
DBEU 7 716 693 700
GSUS 6 953 559 463
GSID 6 953 559 463
VIDY.TO 5 280 568 176
XEU.TO 4 279 534 537
JHMD 3 917 262 709
XSEA.TO 3 558 444 469
NTSI 3 284 293 547
IVE.AX 3 004 420 502
WVOL.AX 2 891 63 862
VE.TO 2 870 308 838
IQDY 2 254 201 478
XEH.TO 1 908 238 361
XWD.TO 1 728 215 906
XBAL.TO 1 675 209 184
TLTD 1 600 143 019
KOKU 1 527 138 122
XCD.TO 1 469 183 451
EASG 903 81 679
DBAW 790 71 024
WLDR 241 38 941
DMCY 93 8 313
Wiadomości dla Evotec SE
Tytuł Treść Źródło Aktualizacja Link
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations. The collaboration continues a successful partnership on evaluating new treatment regimens aimed at reducing treatment duration and overcoming resistance to current therapies. accessnewswire.com 2025-05-07 05:50:00 Czytaj oryginał (ang.)
Evotec SE (EVO) Q1 2025 Earnings Call Transcript Evotec SE (NASDAQ:EVO ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Volker Braun - Head, Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Conference Call Participants Christian Ehmann - Warburg Research Charles Weston - RBC Joseph Hedden - Rx Securities Fynn Scherzler - Deutsche Bank Douglas Tsao - Wainwright Brendan Smith - TD Cowen Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2025 Conference Call. I am George, the Chorus Call operator. seekingalpha.com 2025-05-06 15:15:23 Czytaj oryginał (ang.)
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment Group revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentum Strong progress in strategic protein degradation partnership with Bristol Myers Squibb Strategy building on technology and science leadership: Focus on high-growth, high-value segments, simplifying the business model and fostering operational excellence 2025 Guidance and 2028 Outlook confirmed HAMBURG, DE / ACCESS Newswire / May 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results for Q1 2025, highlighting progress in strategic partnerships and implementation of measures to generate sustainable profitable growth. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "With € 200 m of revenues we ended Q1 2025 slightly ahead of our expectation, despite a soft drug discovery market environment. accessnewswire.com 2025-05-06 05:20:00 Czytaj oryginał (ang.)
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025 HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. accessnewswire.com 2025-04-29 08:30:00 Czytaj oryginał (ang.)
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs Performance-based and program-based payments of in total US$ 75 m to Evotec HAMBURG, DE / ACCESS Newswire / April 24, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced further significant progress of the Company's strategic research collaboration with Bristol Myers Squibb relating to building a high value molecular glue-based pipeline for unmet medical needs. Performance-based and program-based achievements trigger payments of in total US$ 75 m to Evotec. accessnewswire.com 2025-04-24 05:50:00 Czytaj oryginał (ang.)
Evotec SE (EVO) Q4 2024 Earnings Call Transcript Evotec SE (NASDAQ:EVO ) Q4 2024 Earnings Conference Call April 17, 2025 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Paul Hitchin - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Aurélie Dalbiez - Chief People Officer Conference Call Participants Christian Ehmann - Warburg Research Michael Ryskin - Bank of America Charles Weston - RBC Capital Markets Brendan Smith - TD Cowen Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Full-Year Result 2024 Analyst Call. I am Yusuf, the Chorus Call operator. seekingalpha.com 2025-04-17 18:24:50 Czytaj oryginał (ang.)
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence Strong Q4 2024 revenue and EBITDA results in spite of challenging market conditions. Full year guidance met, with liquidity significantly improved Priority Reset on track to deliver annualised recurring gross savings of € 40 m 2025 guidance: group revenues to grow 5 - 10 % (€ 840 - 880 m); 2028 outlook foresees revenue CAGR2024-2028 between 8 - 12% and generation of EBITDA margin above 20 % HAMBURG, GERMANY / ACCESS Newswire / April 17, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process. accessnewswire.com 2025-04-17 05:45:00 Czytaj oryginał (ang.)
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025 HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April 2025. The Company is going to host a conference call to discuss 2024 results as well as to provide an update on the concluded strategic review process. accessnewswire.com 2025-04-10 10:00:00 Czytaj oryginał (ang.)
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY). The latest scientific achievement in the partnership has triggered a research payment of US$20 m to Evotec, enabling further development of a promising pre-clinical programme in neurodegeneration. accessnewswire.com 2025-03-04 03:45:00 Czytaj oryginał (ang.)
Evotec Announces Change in Management Board Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025 Paul Hitchin appointed to succeed as Chief Financial Officer effective 1 March 2025 HAMBURG, GERMANY / ACCESS Newswire / February 26, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Chief Financial Officer, Laetitia Rouxel, will step down from her role of Chief Financial Officer effective 28 February 2025 and leave the Company effective 31 March 2025 to pursue other opportunities. Laetitia Rouxel joined Evotec in April 2023 as Chief Financial Officer and member of the Management Board of Evotec. accessnewswire.com 2025-02-26 04:00:00 Czytaj oryginał (ang.)
Advancing Data Centric AI in Healthcare and Life Sciences - Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Elucidata Strengthens Leadership with Former CEO of Evotec and Ex-McKinsey Senior Partner. businesswire.com 2025-02-19 09:55:00 Czytaj oryginał (ang.)
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). accessnewswire.com 2025-01-22 04:00:00 Czytaj oryginał (ang.)
Evotec: Some Recovery Has Come, But Much More Is Expected Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside. seekingalpha.com 2024-12-29 14:30:30 Czytaj oryginał (ang.)
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai. accesswire.com 2024-12-11 04:00:00 Czytaj oryginał (ang.)
Evotec Announces Change in Management Board Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024 Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. accesswire.com 2024-11-29 04:00:00 Czytaj oryginał (ang.)
Comment on Withdrawn Non-Binding Offer HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for EUR11.00 per share in cash. The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec. accesswire.com 2024-11-22 13:15:00 Czytaj oryginał (ang.)
Halozyme withdraws $2.1 bln buyout offer for Evotec Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions. reuters.com 2024-11-22 10:55:45 Czytaj oryginał (ang.)
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.   Helen Torley, president and chief executive officer of Halozyme , shared the following statement: "We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees. prnewswire.com 2024-11-22 10:35:00 Czytaj oryginał (ang.)
Halozyme CEO: Evotec Is Poised for Growth Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology. youtube.com 2024-11-18 18:00:16 Czytaj oryginał (ang.)
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO , Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders. prnewswire.com 2024-11-18 09:00:00 Czytaj oryginał (ang.)
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion On Thursday, Halozyme Therapeutics, Inc.  HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion). benzinga.com 2024-11-15 14:56:11 Czytaj oryginał (ang.)
Comment on Media Report HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements. accesswire.com 2024-11-14 19:30:00 Czytaj oryginał (ang.)
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024, the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 77% to Evotec's last three-month volume weighted average price on October 15, 2024. prnewswire.com 2024-11-14 18:15:00 Czytaj oryginał (ang.)
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday. reuters.com 2024-11-14 18:09:03 Czytaj oryginał (ang.)
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal Germany-based Evotec SE EVO is trading on Monday after a report that suggests the company is a takeover target. benzinga.com 2024-11-11 12:52:42 Czytaj oryginał (ang.)
Evotec SE (EVO) Q3 2024 Earnings Call Transcript Evotec SE (NASDAQ:EVO ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Volker Braun - Head of Investor Relations Christian Wojczewski - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer & Site Head Toulouse Conference Call Participants Charles Weston - RBC Capital Markets Michael Ryskin - Bank of America Christian Ehmann - Warburg Research Benjamin Jackson - Jefferies Joseph Hedden - Rx Securities Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Nine Months 2024 Capital Market Briefing Conference Call. I am Sachin, the Chorus Call Operator. seekingalpha.com 2024-11-06 21:11:11 Czytaj oryginał (ang.)
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions Robust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnerships Successful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutions Priority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced its financial results and corporate updates for the third quarter of 2024, highlighting strategic progress across key partnerships and operations. accesswire.com 2024-11-06 03:20:00 Czytaj oryginał (ang.)
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners Transaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth drivers New ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) has announced the sale of its chemical API manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, to Monacum Partners GmbH - a Munich based Private Equity firm. This transaction forms part of Evotec's "Priority Reset" initiative launched in April 2024, which aims to foster profitable growth by refining the company's operational footprint and focusing on its primary growth sectors and core competencies. accesswire.com 2024-11-05 03:50:00 Czytaj oryginał (ang.)
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024 HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024. The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. accesswire.com 2024-10-30 05:30:00 Czytaj oryginał (ang.)
Evotec and Bristol Myers Squibb Expand Proteomics Partnership Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec receives a US$ 50 m payment from Bristol Myers Squibb; potential programme-based milestone payments contribute to the deal value HAMBURG, GERMANY / ACCESSWIRE / October 23, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a programme-based payment of US$ 50 m to Evotec. accesswire.com 2024-10-23 06:00:00 Czytaj oryginał (ang.)
Kia Gwangmyeong EVO Plant Opens to Significantly Expand EV Production Kia celebrates the completion of Hyundai Motor Group's first dedicated EV manufacturing facility Kia Gwangmyeong EVO Plant, located at Kia Autoland Gwangmyeong, to mass-produce Kia EV3 and EV4 models The new facility to have production capacity of 150,000 units per year Previous internal combustion engine (ICE) vehicle plant transformed to facilitate EV production and accelerate delivery of Kia's strategic sustainable manufacturing and mobility goals Cutting-edge manufacturing initiatives include water-based painting as well as automated processes The EVO Plant to set a new era for Kia's move towards electrification, through production of the brand's high quality EV lineup SEOUL, South Korea, Sept. 26, 2024 /PRNewswire/ -- Kia Corporation has today celebrated the opening of Kia Gwangmyeong EVO Plant, Hyundai Motor Group's (the Group) first dedicated EV manufacturing facility. prnewswire.com 2024-09-27 03:01:00 Czytaj oryginał (ang.)
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy. benzinga.com 2024-09-26 14:33:17 Czytaj oryginał (ang.)